WO2005091857A3 - 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders - Google Patents

1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders Download PDF

Info

Publication number
WO2005091857A3
WO2005091857A3 PCT/US2005/005367 US2005005367W WO2005091857A3 WO 2005091857 A3 WO2005091857 A3 WO 2005091857A3 US 2005005367 W US2005005367 W US 2005005367W WO 2005091857 A3 WO2005091857 A3 WO 2005091857A3
Authority
WO
WIPO (PCT)
Prior art keywords
naphthyridine
derivatives
related disorders
treat diabetes
diabetes
Prior art date
Application number
PCT/US2005/005367
Other languages
French (fr)
Other versions
WO2005091857A2 (en
Inventor
Rainer Heurich
Original Assignee
Bayer Pharmaceuticals Corp
Rainer Heurich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp, Rainer Heurich filed Critical Bayer Pharmaceuticals Corp
Publication of WO2005091857A2 publication Critical patent/WO2005091857A2/en
Publication of WO2005091857A3 publication Critical patent/WO2005091857A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates generally to naphthyridine derivatives of the formula (A) wherein one of U, X, Y and Z is nitrogen and the others are C-R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine and 1,8-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.
PCT/US2005/005367 2004-03-12 2005-02-24 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders WO2005091857A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55297104P 2004-03-12 2004-03-12
US60/552,971 2004-03-12

Publications (2)

Publication Number Publication Date
WO2005091857A2 WO2005091857A2 (en) 2005-10-06
WO2005091857A3 true WO2005091857A3 (en) 2006-10-05

Family

ID=35056657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005367 WO2005091857A2 (en) 2004-03-12 2005-02-24 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders

Country Status (6)

Country Link
AR (1) AR048088A1 (en)
GT (1) GT200500049A (en)
PE (1) PE20060332A1 (en)
TW (1) TW200538124A (en)
UY (1) UY28805A1 (en)
WO (1) WO2005091857A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9199982B2 (en) 2011-09-02 2015-12-01 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9309251B2 (en) 2012-04-02 2016-04-12 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors
US9403847B2 (en) 2009-12-18 2016-08-02 Incyte Holdings Corporation Substituted heteroaryl fused derivatives as P13K inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015917A2 (en) * 2007-05-14 2009-02-05 F. Hoffmann-La Roche Ag Dihydroquinone and dihydronaphthridine inhibitors of jnk
FR2952934B1 (en) * 2009-11-23 2012-06-22 Sanofi Aventis PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
CA2839395A1 (en) * 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
ES2843522T3 (en) 2015-02-27 2021-07-19 Incyte Corp PI3K inhibitor salts and processes for their preparation
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2018102885A1 (en) * 2016-12-09 2018-06-14 Bionomics Limited Modulators of nicotinic acetylcholine receptors and uses thereof
JOP20180097B1 (en) * 2018-10-22 2023-03-28 Univ Of Jordan 1,8-naphthyridine gluosamine derivatives,their use in the treatment of microbial infections,and amethod for preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195087A (en) * 1976-12-10 1980-03-25 Abic, Ltd. Derivatives of naphthyridine
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195087A (en) * 1976-12-10 1980-03-25 Abic, Ltd. Derivatives of naphthyridine
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940752B2 (en) 2009-06-29 2015-01-27 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9434746B2 (en) 2009-06-29 2016-09-06 Incyte Corporation Pyrimidinones as PI3K inhibitors
US9403847B2 (en) 2009-12-18 2016-08-02 Incyte Holdings Corporation Substituted heteroaryl fused derivatives as P13K inhibitors
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9527848B2 (en) 2010-12-20 2016-12-27 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
US9199982B2 (en) 2011-09-02 2015-12-01 Incyte Holdings Corporation Heterocyclylamines as PI3K inhibitors
US9309251B2 (en) 2012-04-02 2016-04-12 Incyte Holdings Corporation Bicyclic azaheterocyclobenzylamines as PI3K inhibitors

Also Published As

Publication number Publication date
TW200538124A (en) 2005-12-01
PE20060332A1 (en) 2006-06-01
WO2005091857A2 (en) 2005-10-06
UY28805A1 (en) 2005-09-30
GT200500049A (en) 2005-10-24
AR048088A1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
WO2005091857A3 (en) 1,6-naphthyridine and 1,8-naphthyridine derivatives and their use to treat diabetes and related disorders
MXPA04002035A (en) 1, 8-naphthyridine derivatives as antidiabetics.
WO2006011050A3 (en) Pyridine derivatives
NO20055421L (en) Quinoline derivatives as phosphodiesterase inhibitors
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
NO20084129L (en) Pyridine (3,4-B) Pyrazinoner
NO20062591L (en) Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2004043337A3 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
NO20062583L (en) Diphenyllazetidinone derivatives with cholesterol absorption inhibitory activity
NO20074258L (en) Pyridine-2-carboxamide derivatives as MGLUR5 antagonists
NO20062239L (en) New tetrahydrospiro [piperidine-2,7'-pyrrolo [3,2-b] pyridine derivatives and new indole derivatives useful in the treatment of 5-HT6 receptor-related disorders
NO20050828L (en) indole-3-sulfur derivatives
NO20064010L (en) Indazole derivatives and pharmaceutical preparations contain such
IL196543A (en) Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
WO2007087548A3 (en) Chemical compounds
TW200615266A (en) Organic compounds
WO2005115470A3 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING β-CARBOLINE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF CANCER
WO2004009549A3 (en) Piperidines useful for the treatment of central nervous system disorders
ES2195785A1 (en) Pyridazin-3(2h)-one derivatives as pde4 inhibitors
NO20082496L (en) pyrazine derivatives
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
MX2007002324A (en) Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof.
WO2005080352A3 (en) Quinazoline derivatives and therapeutic use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase